Full-Time
Confirmed live in the last 24 hours
Biotech startup developing innovative medicines
$239k - $261.3k/yr
Expert
New York, NY, USA
This role will require a minimum of 3 days a week of onsite presence in our Jersey City (NJ) office.
Get referrals →
You have ways to get a Eikon Therapeutics referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 9 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Eikon Therapeutics develops new medicines in the pharmaceutical industry by studying biological systems to identify drug targets. They utilize a proprietary single-molecule tracking platform to visualize protein movements in living cells, combined with artificial intelligence and automation for precise analysis of molecular interactions. Their diverse team integrates science and engineering to create therapies aimed at improving the lives of patients with serious diseases. Eikon's goal is to explore cell and molecular biology in innovative ways to develop effective treatments.
Company Size
201-500
Company Stage
Series D
Total Funding
$1.1B
Headquarters
Hayward, California
Founded
2019
Help us improve and share your feedback! Did you find this helpful?
401(k) Company Match
Medical (premiums covered by Eikon at 95%)
Dental Insurance
Vision Insurance
Mental Health Support
Unlimited Paid Time Off
Paid Holidays
Life Insurance
Enhanced Parental Leave
Daily subsidized lunch program
Dr. Baynes, who currently serves as executive vice president and chief medical officer of Eikon Therapeutics, has had a distinguished career in hematology and oncology and over 22 years of clinical leadership experience in pharmaceutical and biotech companies.
Another significant entity, Soros Capital - managed by Robert Soros, son of the billionaire George Soros - participated in a $350.7 million financing round for Eikon Therapeutics.
Eikon Therapeutics, Inc., a pivotal-stage biotechnology company that integrates advanced engineering with cutting-edge molecular and cell biology to a
Eikon Therapeutics, led by former Merck RD head Roger Perlmutter, raised $350 million, bringing its total funding to $1.1 billion. The funds will support the clinical development of cancer drugs, including an immunotherapy in Phase 3 for melanoma and two PARP inhibitors. The financing round included investors like Lux Capital and Alexandria Venture Investments.
Eikon Therapeutics Inc. has closed a $351 million series D funding round, marking the largest venture capital round of 2025 and the first series D of the year. This funding supports Eikon as it enters phase III in cancer treatment development.